We assessed the risk of developing second malignancies in children treated for Hodgkin's lymphoma (HL), the majority of whom received chemotherapy only.
introduction Pediatric Hodgkin's lymphoma (HL) is a common malignancy with an overall survival (OS) rate that exceeds 85% [1] [2] [3] [4] [5] . As cure rates have improved, long-term treatment sequelae, particularly second malignancies, have become a major issue for survivors [6] [7] [8] [9] [10] [11] [12] . The cumulative incidence of second malignancy is higher in patients treated for HL compared with other cancers [13, 14] , affecting up to a quarter of survivors at 30 years, with the majority consisting of solid tumors [6] [7] [8] [9] [10] [11] [12] . Treatment factors, genetic variability and underlying immune deficiencies have each been proposed as contributing to the high rate of secondary malignancies [15] [16] [17] [18] .
It is well established that exposure to ionizing radiation increases the risk of solid tumors [19] . Radiotherapy (RT) has been an integral part of many childhood HL treatment protocols, and as a consequence, the majority of long-term survivors have been exposed to RT. Therefore, the precise role of RT in the development of secondary solid tumors compared with other factors is not known. Furthermore, the relative risk of developing second solid tumors for children treated without RT is also unknown. One of the largest reported cohorts to date of children treated without RT identified RT as a significant risk factor for development of secondary solid tumors and suggested that there is no increased risk for children treated with chemotherapy alone [8] . However, non-RT patients only comprised 8% of the total treatment cohort and are likely to have had different clinical characteristics from patients treated with multimodal therapy [8] . A recent study that evaluated the long-term incidence of second malignancies in survivors of childhood HL who had been treated with reduced dose radiation and chemotherapy found that despite the reduction in radiation dosage, there was no correlative reduction in the incidence of second malignancies [20] . Other long-term studies in children addressing this issue are lacking.
In Australia over the past 30 years, it has been common practice to treat pediatric HL patients with chemotherapy original article For the purpose of analysis, patients were divided into two groups-those who received RT and those who did not receive RT. Patients who initially did not receive RT but subsequently relapsed and were salvaged with protocols that included RT are included in the 'no RT' group for analysis of relapse and mortality but are included in the 'RT' group for analysis of second solid malignancies and treatment-related mortality. Measures of outcome and second malignancies were taken from the time of initial diagnosis of HL.
statistical analysis
Pearson's Chi-squared analysis was used to assess for potential differences between treatment groups. Variables analyzed were sex, age at HL diagnosis, year of HL diagnosis, relapsed disease, stage at diagnosis, B symptoms, splenectomy, treatment with RT, dose of RT and number of cycles of chemotherapy. Standardized incidence ratios (SIR) were calculated by dividing the number of cases of second solid tumors by the number of expected cases from general population data, matched for age. Population data were obtained from the Australian Institute of Health and Welfare. Absolute excess risk (AER), expressed per 1000 person-years, was determined by subtracting the expected number of second solid tumors in the cohort from the observed number, dividing the difference by personyears of follow-up, and multiplying this number by 1000. Cumulative incidence was calculated using the Kaplan-Meier method. Kaplan-Meier curves were produced using Graphpad Prism version 5.02. P values for curves were produced using log-rank (Mantel-Cox) test. Nelson-Aalen cumulative hazard estimates were generated in STATA (version 10) by taking death of other causes as competing risk. Univariate and multivariate Cox regressions were used to estimate the hazard ratio of second solid malignancies. Age at the diagnosis of second solid malignancies, at death or at last follow up was the time variable. Cox regressions were carried out for year at diagnosis (earlier than 1986 versus 1986 or later), age at diagnosis of HL (<10 years versus ‡10 years), stage of HL (I and II versus III and IV), B symptoms (yes versus no), sex (male versus female) and treatment group (RT versus no RT). B symptoms were not included in the multivariate analysis due to limited number of cases (n = 16). A P value <0.05 was considered as statistically significant. All statistical tests were two tailed.
results

patient characteristics
A total of 142 patients with pediatric HL were identified and included in the analysis. Chemotherapy regimens for patients are shown in Table 1 . The type of chemotherapy and the number of cycles of chemotherapy per patient were not significantly different between the two groups (4.6 versus 4.9; P = 0.59). Of the 142 patients, 85 patients initially did not receive RT, whereas 57 received RT alone or in combination with chemotherapy. Six patients who were treated initially with chemotherapy alone subsequently relapsed and were salvaged with regimens including RT. One patient was treated with surgery alone. Therefore, 63 patients received RT at some point in their treatment. Of these patients, 18 (28%) received £25Gy and 29 (46%) received >25Gy, and there were insufficient data in 16 patients (25%). The RT and no-RT groups were equally matched for sex, age at diagnosis, stage at diagnosis, hematopoietic stem cell transplant, use of chemotherapy and presence of B symptoms (Table 2 ). Median follow-up was significantly longer in the RT group (230 months versus 174 months; P = 0.002). Only eight patients underwent splenectomy, all received RT as part of their treatment.
secondary hematological malignancy
There were three patients who developed a secondary hematological malignancy. Two patients who did not receive RT developed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at 28 and 33 months, respectively, after their initial diagnoses. It is noteworthy that the patient who developed AML was treated with 15 cycles of chlorambucil, vincristine, procarbazine and prednisone. He eventually died due to AML. One patient who received both RT and chemotherapy developed MDS. In the total cohort of 142 patients, there were a total of 16 secondary solid tumors that developed in 14 patients (Table 3) at a median of 168 months after initial HL diagnosis in the RT group and 155 months in patients who did not receive RT (P = 0.92). Second solid tumors occurred in 12 patients (19%) in the RT group and 2 patients (2.5%) in the non-RT group (P = 0.001). Two patients who received RT developed third solid tumors (Table 3) . Histological diagnoses of second tumors are listed in Table 3 . At least 75% of solid tumors in the RT group occurred within the field of radiation; however, the true figure is likely to be higher as the precise locations of the melanomas could not be determined. Among patients who did not receive RT, one patient developed a thyroid carcinoma and another patient developed a Kaposi sarcoma (Table 3 ). This patient was not human immunodeficiency virus positive but did not have investigations for any other underlying immune deficiency. For the entire group, the 20-and 30-year cumulative incidence of second solid tumors was 11.9% [95% confidence interval (CI) 1.8-32.5] and 16.8% (95% CI 3.7-38.1), respectively ( Figure 1A) . Twenty-and 30-year cumulative incidence of second solid malignancies in patients who received RT was 18.1% (95% CI 3.51-41.85) and 24Á7% (95% CI 7.27-47.4; Figure 1B) , respectively. For patients treated without RT, 20-year cumulative incidence of second solid malignancies was 5.80% (95% CI 0-58.9; Figure 1B ). In contrast to RT patients, the cumulative incidence remained unchanged at 5.8% after 30 years follow-up. Compared with age matched population data, the SIR for second solid tumors for patients who received RT was significantly elevated at 236 (95% CI 112.2-359.0) with an AER of 10.9 per 1000 patient-years. In comparison, the SIR for those who did not receive RT was 43.6 (95% CI 0-103.9) and AER was 1.6 per 1000 patient-years. The relative risk of developing a second solid tumor in the RT group was 5.51 (95% CI; 1.22-24.99) fold higher than the no-RT group and appeared to be increasing with time. Figure 2 demonstrates the Nelson-Aalen cumulative hazard estimates of secondary solid tumors with death of other causes being competing risk. The cumulative hazard of secondary solid tumors was significantly higher for RT patients compared with non-RT patients (P = 0.03). The hazard has increased with the advance of age (Figure 2 ).
univariate and multivariate analyses
There was a significantly higher number of second solid tumors among patients who received RT compared with those who did not ( Figure 1B ; 19.0% versus 2.5%; P = 0.013). When the data were censored at 170 months to account for the shortened follow-up time in the no-RT patients, the result remained significant (P = 0.01; log rank). There was no significant difference in the number of chemotherapy cycles received in patients that developed second solid tumors (3.8 cycles versus 4.9 cycles; P = 0.35). The mean dose of RT was not significantly higher in those patients treated with RT who developed a second solid tumor (33.1 versus 30.1 Gy; P = 0.30), and there was no difference in second solid tumor incidence in those who received <25Gy compared with those who received >25Gy (11% versus 13%; P = 0.30). To further quantify the risk of RT on second solid tumors, comparison was made between the incidence of in-field second tumors and the incidence in patients who did not receive RT. There remained a significant increased risk of second tumors in the RT group (17.7% versus 5.80%; P = 0.04). In both univariate and multivariate competing risk analyses, RT was the only significant factor for the development of second solid tumors (with hazard ratio of 6.7; P = 0.03; 95% CI 1.2-34.8) (Tables 4 and 5 ). Interestingly, the presence of B symptoms did border on significance (P = 0.051), which has not previously been identified as a risk factor in this population. As there were only 16 patients with B symptoms, however, it was not included in the multivariate analysis.
second tumor outcomes
There were two deaths due to secondary solid tumors in the RT group, one patient with non-Hodgkin's lymphoma and one with primitive neuro-ectodermal tumor. One patient who did not receive radiation therapy died from Kaposi's sarcoma. The median length of follow-up after diagnosis of second solid tumors is 71.5 months.
survival
The overall 5-year survival for the entire cohort was 94.4% (95% CI 89.1-97.2), and there was no significant difference in 5-year OS between those patients who received RT and those who did not (96.5% versus 92.9%, respectively; P = 0.47). Similarly, there was no significant difference in death from HL, 
discussion
To our knowledge, this is the largest reported long-term follow-up study for second solid tumors in pediatric HL patients in which the majority of children were treated with chemotherapy only. Within the confines of a retrospective study, the results suggest that the administration of RT and the presence of B symptoms at diagnosis are the two most significant factors affecting the risk of developing second solid tumors later in life. Children treated with chemotherapy alone had a significantly lower incidence of second solid tumors of 5% at 30 years follow-up compared with 25% for those who received radiation therapy, with a hazard ratio of 6.7.
While there was a significant difference in length of follow-up between the two treatment groups, the difference in outcome was independent of this factor. A limitation of the study is the uncertainty as to why select patients received RT as this was up to the discretion of the treating physician. Regardless of the reasons, the findings in this study help to gauge the long-term risk of second solid tumors rather than aid in advising on initial treatment strategies. These findings have significant implications for lifestyle issues, cancer surveillance and preventative strategies in childhood HL survivors.
A strength of this study over previous reports is the use of both clinical records data and independently reported cancer registry data. This allowed for a comprehensive assessment of treatments administered, including at relapse, and facilitated the enhanced surveillance of patients lost to clinical follow-up. Individuals originally diagnosed with a childhood cancer in NSW, who had developed a second cancer after relocating to another state or territory, were also recorded on the NCCR. While it is possible that some patients may have been missed due to relocation overseas, the overall data set is more likely to be complete than by relying on either medical record or centralized database review alone.
The largest previously reported study of second malignancies in pediatric HL patients included 106 subjects who did not receive RT as part of their treatment, and only two of these patients subsequently developed second solid tumors [8] . However, the patient cohort treated with chemotherapy comprised only 8% of the total patient population and it is likely that they represented a distinct group in whom RT was omitted due to underlying differences in patient characteristics. Thus, the incidence of second solid tumors in non-RT treated patients in this study may not be generalized to all patients with HL. During the period of our study, it was common practice in Australia to exclude RT from treatment regimens regardless of disease stage or original article Annals of Oncology baseline characteristics [21] . Thus, the results of this study can more readily be generalized to all patients with HL.
Our results help to more precisely define the risk of developing second solid tumors for patients treated with chemotherapy only. While the SIR of second solid tumors in these chemotherapy only treated patients was higher than the general population, this difference was not statistically significant, likely due to the relatively small sample size, almost 1000 chemotherapy only treated patients would need to be analyzed to determine the significance of a small increase in SIR. It is important to note that despite not receiving therapeutic doses of radiation, all patients were subjected to multiple imaging studies for tumor surveillance, including computed tomography (CT) scans and gallium scans, and were thus exposed to incidental radiation, which increased their risk of second solid tumors. Each childhood abdominal CT scan has been estimated to result in an excess lifetime cancer mortality risk of 0.18% [22] . Our data does make it definitively clear; however, that the omission of radiation therapy substantially diminishes that risk by a factor of 5.5-fold.
The absence of breast cancer in our cohort is noteworthy, as it has been reported as the most common solid tumor in female patients successfully treated for HL [6] [7] [8] [9] with cumulative incidence ranging from 9.9% to 34% at 25 years follow-up [6] [7] [8] [9] . Risk factors reported are RT during puberty (>12 years), higher doses of RT, mantle field irradiation and greater time of follow-up [23] [24] [25] [26] [27] [28] . In our cohort, there was a relatively small number of female patients who received RT involving breast tissue (n = 11). All these patients received alkylating agents, which has been shown to have a protective effect against breast cancer [26] [27] [28] ; only four received mantle field irradiation and the majority of these patients were prepubertal during treatment of their HL. These factors and the avoidance of RT altogether for the majority of patients may account for the absence of breast cancer in our population. Strategies to reduce the incidence of second malignancies in childhood HL survivors have included the use of low dose involved the field of RT. However, the first report on the longterm outcomes for such patients has found the rate of second solid malignancies to be 14% at 20 years [20] , in stark contrast to the outcomes reported here for patients treated with chemotherapy alone (5.8% at 20 years). It may therefore be appropriate to consider the development of treatment strategies that eliminate the use of radiation therapy for select patients. While encouragingly, we found no difference in OS, event-free survival or treatment-related mortality based on the use of RT, these results must be interpreted with caution given the retrospective nature of this study. Further prospective studies may help determine whether this strategy may be appropriate for specific subgroups of patients.
Finally, a previously unreported finding of this study is the association of B symptoms at diagnosis of HL with the subsequent development of second solid tumors. This was an unexpected finding, and although the association bordered on significance, due to the small number of patients (n = 16), it requires verification in a large independent sample before any conclusions can be drawn. If substantiated, it is possible that the presence of B symptoms may be a sign of an underlying immunodeficient state, which in turn may render the patient more susceptible to second malignancies.
In conclusion, patients treated without radiation therapy for childhood HL have a substantially reduced incidence of second solid tumors. These results will help to better inform treating physicians, patients and insurers. They will facilitate the development of more effective strategies for both the treatment and the long-term follow-up of children with HL.
